Beta
215808

A new approach in treatment of chronic murine models of toxoplasmosis using nitrofurantoin antibiotic.

Article

Last updated: 22 Jan 2023

Subjects

-

Tags

Medical Parasitology

Abstract

Background: Standard therapies for toxoplasmosis have serious adverse effects and can't eliminate cyst stage of chronic infection. Highly effective medications with few adverse effects are required.
Objective: To determine the efficacy of nitrofurantoin in the treatment of chronic toxoplasmosis as a means of overwhelming the limitations of other standard medications.
Materials and Methods: 42 laboratory-bred Swiss female albino mice were included. Six mice were left as uninfected, untreated group (G 1). The rest (12mice/ each group) were experimentally infected orally with T. gondii strain (ME49). Six weeks post infection the experimental mice were divided into four groups .Group1:uninfected, untreated ; Group2:infected, untreated mice (infected control); Group3:infected treated mice with nitrofurantoin for two weeks and Group 4: infected mice treated with a combination of nitrofurantoin and spiramycin for two weeks . Sixty days after infection, all mice were slaughtered. Parasitological (brain cyst count) and histological (using hematoxylin and eosin) measures were used to assess the therapeutic impact of nitrofurantoin in chronically infected mice (H & E).
Results: High significant reduction of mean brain cyst count was observed in nitrofurantoin monotherapy group in comparison with the infected control group. The combination-treated group had the best treatment efficacy, with the highest rates of brain cyst decrease. Histopathological studies of the brain tissues showed obvious correlation with the results of the brain cyst counts.
Conclusion: Nitrofurantoin is a possible anti-T.gondii option for clinical usage in chronic toxoplasmosis, as it enhances the antitoxoplasmic effect of standard toxoplasmosis treatment.

DOI

10.21608/zumj.2022.112316.2440

Keywords

Keywords: Toxoplasma gondii, chronic toxoplasmosis, Nitrofurantoin

Authors

First Name

Karim

Last Name

Abdallah

MiddleName

fettoh

Affiliation

parasitology department ,banha faculty of medicine ,banha university, banha ,egypt

Email

karim65@yahoo.com

City

banha

Orcid

-

First Name

mohamad

Last Name

saleh

MiddleName

hussien

Affiliation

parasitology department ,banha faculty of medicine ,banha university, banha ,egypt

Email

mohamad1966@yahoo.com

City

banha

Orcid

-

First Name

shereen

Last Name

kishik

MiddleName

-

Affiliation

parasitology department ,banha faculty of medicine ,banha university, banha ,egypt

Email

dr_sheren33@gmail.com

City

banha

Orcid

-

First Name

ashraf

Last Name

barakat

MiddleName

mohamed

Affiliation

Zoonotic Diseases Department National Research Center, Giza, Egypt.

Email

dr.barakat65@yahoo.com

City

Giza

Orcid

-

First Name

basma

Last Name

Ali

MiddleName

tharwat

Affiliation

parasitology department ,banha faculty of medicine ,banha university, banha ,egypt

Email

basma234@yahoo.com

City

banha

Orcid

-

First Name

asmaa

Last Name

elkholy

MiddleName

abdelmoniem

Affiliation

parasitology department,faculty of medicine, Banha university,Banha ,Egypt.

Email

asmaakholy787@gmail.com

City

banha

Orcid

-

Volume

28

Article Issue

5

Related Issue

36360

Issue Date

2022-09-01

Receive Date

2021-12-27

Publish Date

2022-09-01

Page Start

1,169

Page End

1,175

Print ISSN

1110-1431

Online ISSN

2357-0717

Link

https://zumj.journals.ekb.eg/article_215808.html

Detail API

https://zumj.journals.ekb.eg/service?article_code=215808

Order

912

Type

Original Article

Type Code

273

Publication Type

Journal

Publication Title

Zagazig University Medical Journal

Publication Link

https://zumj.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023